Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation

US6284871A · kind A · utility

Assignee

• Stiching Centraal Laboratorium van de Bloedtransfusiedienst van Nederlandse Rode Kruis · NL

Inventors

• Koenraad Mertens · Leiden, NL
• Petrus Lenting · Blois, FR

Key dates

• Filing date: Dec 9, 1997
• Grant date: Sep 4, 2001
• Expiry date: Dec 9, 2017

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/83
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to biologically active peptides which specifically inhibit the Factor IX-dependent pathway of blood coagulation. These peptides are based on a specific motif which represents a sequence of Factor VIII (amino acid 1811-1818) involved in binding to activated Factor IX as well as to the intact Factor IX zymogen. Binding of said peptides to Factor IX or activated derivatives thereof effectively inhibits complex assembly with Factor VIII. These peptides thereby specifically interfere in the Factor IX-dependent pathway of thrombin formation, while leaving other haemostatic pathways unaffected. By virtue of this unique specificity, the peptides of this invention are particularly useful in novel pharmaceutical compositions for the treatment of thrombotic disorders.